JP7644713B2 - アビラテロンプロドラッグ - Google Patents

アビラテロンプロドラッグ Download PDF

Info

Publication number
JP7644713B2
JP7644713B2 JP2021552742A JP2021552742A JP7644713B2 JP 7644713 B2 JP7644713 B2 JP 7644713B2 JP 2021552742 A JP2021552742 A JP 2021552742A JP 2021552742 A JP2021552742 A JP 2021552742A JP 7644713 B2 JP7644713 B2 JP 7644713B2
Authority
JP
Japan
Prior art keywords
abiraterone
oil
pharma
pharmaceutical composition
decanoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021552742A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523819A5 (https=
JP2022523819A (ja
JPWO2020180942A5 (https=
Inventor
マシュー ジェイ． シャープ
ウィリアム アール． ジュニア ムーア
Original Assignee
プロペラ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロペラ セラピューティクス インコーポレイテッド filed Critical プロペラ セラピューティクス インコーポレイテッド
Publication of JP2022523819A publication Critical patent/JP2022523819A/ja
Publication of JP2022523819A5 publication Critical patent/JP2022523819A5/ja
Publication of JPWO2020180942A5 publication Critical patent/JPWO2020180942A5/ja
Application granted granted Critical
Publication of JP7644713B2 publication Critical patent/JP7644713B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021552742A 2019-03-06 2020-03-04 アビラテロンプロドラッグ Active JP7644713B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962814568P 2019-03-06 2019-03-06
US62/814,568 2019-03-06
US201962849259P 2019-05-17 2019-05-17
US62/849,259 2019-05-17
PCT/US2020/020915 WO2020180942A1 (en) 2019-03-06 2020-03-04 Abiraterone prodrugs

Publications (4)

Publication Number Publication Date
JP2022523819A JP2022523819A (ja) 2022-04-26
JP2022523819A5 JP2022523819A5 (https=) 2023-03-09
JPWO2020180942A5 JPWO2020180942A5 (https=) 2023-03-09
JP7644713B2 true JP7644713B2 (ja) 2025-03-12

Family

ID=70190090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021552742A Active JP7644713B2 (ja) 2019-03-06 2020-03-04 アビラテロンプロドラッグ

Country Status (15)

Country Link
US (4) US10792292B2 (https=)
EP (2) EP4286006A3 (https=)
JP (1) JP7644713B2 (https=)
KR (1) KR102879575B1 (https=)
CN (3) CN114026106B (https=)
AU (1) AU2020232706B2 (https=)
BR (1) BR112021017377A2 (https=)
CA (1) CA3131034A1 (https=)
DK (1) DK3935068T3 (https=)
ES (1) ES2964818T3 (https=)
IL (1) IL286048B2 (https=)
MX (1) MX2021010553A (https=)
PL (1) PL3935068T3 (https=)
WO (1) WO2020180942A1 (https=)
ZA (1) ZA202107278B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023539371A (ja) * 2020-09-02 2023-09-13 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7644713B2 (ja) * 2019-03-06 2025-03-12 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ
US12347562B2 (en) * 2019-12-26 2025-07-01 Cerner Innovation, Inc. Decision support application for PCOS
CN113929727A (zh) * 2020-09-28 2022-01-14 南京易腾药物研究院有限公司 阿比特龙酯类衍生物及其制备方法和应用
CN117120034A (zh) * 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药
CN113061154B (zh) * 2021-03-25 2022-07-08 天津海润家和创新医药研究有限责任公司 新型注射用阿比特龙衍生物的制备方法和用途
CN113527401A (zh) * 2021-08-26 2021-10-22 雷昊言 一种阿比特龙前体化合物及其制备方法和应用
JP2024533332A (ja) 2021-09-08 2024-09-12 プロペラ セラピューティクス インコーポレイテッド 経口アビラテロン製剤
KR20240167653A (ko) 2022-03-01 2024-11-27 프로펠라 쎄라퓨틱스, 인크. 아비라테론 데카노에이트 프로드러그 및 요법에서의 용도
WO2024107928A1 (en) 2022-11-16 2024-05-23 Propella Therapeutics, Inc. Abiraterone decanoate composition and use in therapy
CN116046950A (zh) * 2023-01-18 2023-05-02 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) 一种检测醋酸阿比特龙中5种杂质的方法
LU506495B1 (en) * 2024-03-01 2025-09-01 Alfasan Nederland B V 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004002321A (ja) 2002-03-11 2004-01-08 Takeda Chem Ind Ltd 性ホルモン依存性疾患治療剤
JP2005533036A (ja) 2002-05-30 2005-11-04 アクゾ・ノベル・エヌ・ベー 油性溶液の自己投与型避妊注射
JP2008546713A (ja) 2005-06-16 2008-12-25 ミリアド ジェネティクス， インコーポレイテッド 薬学的組成物およびその使用
JP2010501575A (ja) 2006-08-25 2010-01-21 クオウガル バイオテクノロジー，インコーポレイテッド 癌を治療するための方法及び組成物
WO2011083830A1 (ja) 2010-01-06 2011-07-14 学校法人関西文理総合学園 新規抗がん剤およびそのスクリーニング方法
JP2018505206A (ja) 2015-02-15 2018-02-22 重慶医薬工業研究院有限責任公司 アビラテロンプロピオネートの結晶形及びその製造方法
JP2018507246A (ja) 2015-03-06 2018-03-15 ザ クリーヴランド クリニック ファウンデーションＴｈｅ Ｃｌｅｖｅｌａｎｄ Ｃｌｉｎｉｃ Ｆｏｕｎｄａｔｉｏｎ ステロイド依存性疾患を治療するためのステロイド代謝の改変

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
EP1488807A4 (en) 2002-03-11 2009-07-08 Takeda Pharmaceutical MEANS FOR THE TREATMENT OF SEXUAL-HORMONE-RELATED DISEASES
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
WO2009009132A1 (en) 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2010091303A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel steroidal cyp17 inhibitors/antiandrogens
EP2506855A4 (en) 2009-11-30 2014-07-30 Harbor Biosciences Inc ANTICARCINOMA COMPOUNDS AND SCREENING METHODS
AU2011343637A1 (en) 2010-12-16 2013-05-30 Biomarin Pharmaceutical Inc. C- 17 -heteroaryl steroidal compounds as inhibitors of CYP11B, CYP17, and/or CYP21
DE102011083725A1 (de) 2011-09-29 2013-04-04 Bayer Pharma AG Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
RS55223B1 (sr) 2011-10-10 2017-02-28 Zach System Postupak za dobijanje 17-supstituisanih steroida
PH12014500943A1 (en) 2011-11-30 2014-06-30 Astrazeneca Ab Combination treatment of cancer
AU2012358219A1 (en) 2011-12-22 2014-07-10 Tokai Pharmaceuticals, Inc. Methods and compositions for combination therapy using P13K/mTOR inhibitors
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
WO2013159225A1 (en) 2012-04-23 2013-10-31 Alphora Research Inc. Process for preparation of 17-substituted steroids
WO2014009434A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014016830A1 (en) 2012-07-25 2014-01-30 Mapi Pharma Ltd. Process and intermediates for the preparation of abiraterone acetate
US20140011992A1 (en) 2012-12-20 2014-01-09 Crystal Pharma, S.A.U. Synthesis of abiraterone and related compounds
SG10201907684PA (en) 2013-01-15 2019-10-30 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
WO2014111815A2 (en) * 2013-01-18 2014-07-24 Cortendo Ab (Publ) Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction
MX2015013247A (es) 2013-03-15 2016-11-25 Iceutica Inc Formulacion de acetato de abiraterona.
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
EP3035938B1 (en) 2013-09-10 2020-08-19 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
ES3063787T3 (en) 2013-10-01 2026-04-20 Novartis Ag Composition comprising a 17 a-hydroxylase/c17,20 lyase (cyp17a1) inhibitor and an akt inhibitor
AU2015224576A1 (en) 2014-03-03 2016-09-22 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
WO2015143004A1 (en) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp. Targeted therapeutics
CN104017045B (zh) * 2014-06-23 2016-01-13 广州艾格生物科技有限公司 甾体cyp17抑制剂的新型药物前体及其应用、制备方法
US9937259B2 (en) 2014-06-27 2018-04-10 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivatives and non-covalent complexes with albumin
EP3193857A4 (en) 2014-09-18 2018-04-11 Iceutica Inc. Abiraterone acetate formulation and methods of use
CN104356191A (zh) 2014-09-29 2015-02-18 上海延安药业（湖北）有限公司 阿比特龙单琥珀酸酯及其制备方法
TWI641616B (zh) 2014-11-28 2018-11-21 四川海思科製藥有限公司 阿比特龍衍生物及其製備方法和醫藥用途
CN104447394B (zh) * 2014-12-17 2017-01-18 成都傲飞生物化学品有限责任公司 一种乌苯美司的新型合成工艺
ES2954596T3 (es) 2015-12-23 2023-11-23 Univ British Columbia Profármacos unidos a lípidos
JP6842474B2 (ja) 2016-02-02 2021-03-17 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． ステロイド系化合物、当該化合物を含む組成物及びその使用
MA45052A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
WO2018071544A1 (en) 2016-10-11 2018-04-19 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivative and formulations thereof
CN106977577A (zh) 2017-04-21 2017-07-25 湖南师范大学 两类阿比特龙衍生物的合成
JP2022523704A (ja) 2019-01-25 2022-04-26 シェンチェン・ファーマシン・カンパニー・リミテッド 医薬組成物
JP7644713B2 (ja) * 2019-03-06 2025-03-12 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ
JP2022525425A (ja) 2019-03-18 2022-05-13 ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー アビラテロン－環状オリゴマー薬学的製剤ならびにその形成方法および投与方法
CN116490165A (zh) 2020-09-02 2023-07-25 普洛佩拉治疗公司 阿比特龙前药
CN113929727A (zh) 2020-09-28 2022-01-14 南京易腾药物研究院有限公司 阿比特龙酯类衍生物及其制备方法和应用
CN117120034A (zh) 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药
JP2024533332A (ja) 2021-09-08 2024-09-12 プロペラ セラピューティクス インコーポレイテッド 経口アビラテロン製剤

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004002321A (ja) 2002-03-11 2004-01-08 Takeda Chem Ind Ltd 性ホルモン依存性疾患治療剤
JP2005533036A (ja) 2002-05-30 2005-11-04 アクゾ・ノベル・エヌ・ベー 油性溶液の自己投与型避妊注射
JP2008546713A (ja) 2005-06-16 2008-12-25 ミリアド ジェネティクス， インコーポレイテッド 薬学的組成物およびその使用
JP2010501575A (ja) 2006-08-25 2010-01-21 クオウガル バイオテクノロジー，インコーポレイテッド 癌を治療するための方法及び組成物
WO2011083830A1 (ja) 2010-01-06 2011-07-14 学校法人関西文理総合学園 新規抗がん剤およびそのスクリーニング方法
JP2018505206A (ja) 2015-02-15 2018-02-22 重慶医薬工業研究院有限責任公司 アビラテロンプロピオネートの結晶形及びその製造方法
JP2018507246A (ja) 2015-03-06 2018-03-15 ザ クリーヴランド クリニック ファウンデーションＴｈｅ Ｃｌｅｖｅｌａｎｄ Ｃｌｉｎｉｃ Ｆｏｕｎｄａｔｉｏｎ ステロイド依存性疾患を治療するためのステロイド代謝の改変

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023539371A (ja) * 2020-09-02 2023-09-13 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ
JP7850366B2 (ja) 2020-09-02 2026-04-23 アステラス ユーエス エルエルシー アビラテロンプロドラッグ

Also Published As

Publication number Publication date
CN120484046A (zh) 2025-08-15
CN120531742A (zh) 2025-08-26
IL286048A (en) 2021-10-31
ES2964818T3 (es) 2024-04-09
US20200368255A1 (en) 2020-11-26
IL286048B2 (en) 2025-03-01
EP4286006A2 (en) 2023-12-06
JP2022523819A (ja) 2022-04-26
PL3935068T3 (pl) 2024-02-26
US11559534B2 (en) 2023-01-24
US20250099489A1 (en) 2025-03-27
KR20210136072A (ko) 2021-11-16
US10792292B2 (en) 2020-10-06
EP4286006A3 (en) 2024-03-20
AU2020232706B2 (en) 2025-10-02
CA3131034A1 (en) 2020-09-10
MX2021010553A (es) 2021-12-15
US20200281945A1 (en) 2020-09-10
WO2020180942A1 (en) 2020-09-10
EP3935068A1 (en) 2022-01-12
IL286048B1 (en) 2024-11-01
KR102879575B1 (ko) 2025-11-03
ZA202107278B (en) 2023-06-28
US20230233582A1 (en) 2023-07-27
BR112021017377A2 (pt) 2021-11-16
CN114026106A (zh) 2022-02-08
CN114026106B (zh) 2025-01-21
EP3935068B1 (en) 2023-09-06
US12138273B2 (en) 2024-11-12
AU2020232706A1 (en) 2021-09-16
DK3935068T3 (da) 2023-12-04

Similar Documents

Publication Publication Date Title
JP7644713B2 (ja) アビラテロンプロドラッグ
US20260014172A1 (en) Abiraterone prodrugs
JP7850366B2 (ja) アビラテロンプロドラッグ
JPWO2020180942A5 (https=)
US20250186463A1 (en) Abiraterone decanoate prodrugs and use in therapy
RU2822219C2 (ru) Пролекарства абиратерона
HK40103488A (en) Abiraterone prodrugs
HK40130201A (zh) 阿比特龙前药
HK40065545A (en) Abiraterone prodrugs
HK40065545B (zh) 阿比特龙前药
HK40096900A (zh) 阿比特龙前药

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230228

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230228

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250228

R150 Certificate of patent or registration of utility model

Ref document number: 7644713

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350